Advanced Bionics designs and manufactures cochlear implants and hearing technology, self-described as providing solutions for individuals with hearing loss.

Advanced Bionics

Abbott develops and delivers health care technologies and products. The company focuses on various sectors of health care, including diagnostics and nutrition. Self-described as a provider of life-changing solutions.

Abbott

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Abiomed, Inc.

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Metric
Company Name	Advanced Bionics	Abbott	Abiomed, Inc.	Alcon Inc.
Symbol			ABMD	ALC
MSH ID	COM:ADVANCEDBIONICS	COM:ABBOTT	COM:ABIOMED	COM:ALCON
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Medical Devices and Diagnostics	Medical - Devices
Country	US	US	US	CH
Stage
Employee Count		10.00K	2.00K	25K
Website	advancedbionics.com	abbott.com	abiomed.com	alcon.com
LinkedIn
Founders

Metric
Market Cap			17.18B	37.60B
Enterprise Value
Monthly Web Traffic	33.21K	873.36K		293
Web Traffic Growth	-0.65	-0.14		-0.72
Valuation
Raised Capital

Metric
Revenue	1.03B	9.46B
Revenue (LTM)
Revenue (NTM)
Gross Profit	843.60M	5.25B
EBITDA	400.78M	2.29B
Operating Income	372.69M	1.04B
Net Income	136.50M	974M
EPS	3	1.98
Diluted EPS	2.98	1.98
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82	0.56
Operating Profit Margin	0.36	0.12
EBITDA Margin	0.39	0.24
Net Profit Margin	0.13	0.11
Return on Equity	0.10	0.10
Return on Assets	0.08	0.04
Return on Capital Employed	0.24	0.04

ADVA

COM:ADVANCEDBIONICS

Advanced Bionics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	126.85	82.75
P/B Ratio	11.52	1.89
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	16.65	5.16
EV Multiple	43.20	36.34

Metric
Days Sales Outstanding	32.05	66.36
Days Payables Outstanding	68.57	75.78
Days Inventory Outstanding	182.31	201.41
Operating Cycle	214.36	282.86
Cash Conversion Cycle	145.80	212.52
Asset Turnover	0.62	0.32

Metric
Operating Cash Flow	285.39M	1.39B
Free Cash Flow	249.63M	537M
Cash Flow to Debt		0.36
Operating Cash Flow/Sales	0.28	0.19
Free Cash Flow Yield	0.01	0.01

Metric
Cash & Equivalents	132.82M	1.09B
Accounts Receivable	5.33M	-110M
Inventory	93.98M	2.32B
Goodwill	76.79M	8.93B
Debt to Capitalization		0.20
Debt to Assets		0.17
Current Ratio	7.05	1.87
Quick Ratio	6.13	1.56

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05	0.01
R&D to Revenue	0.16	0.09
SG&A to Revenue